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Abstract
Background: Barrett’s esophagus (BE) is one of the most common premalignant lesions and can progress to esophageal
adenocarcinoma (EA). The numerous molecular events may play a role in the neoplastic transformation of Barrett’s mucosa
such as the change of DNA ploidy, p53 mutation and alteration of adhesion molecules. However, the molecular mechanism
of the progression of BE to EA remains unclear and most studies of mitochondrial DNA (mtDNA) mutations in BE have
performed on BE with the presence of dysplasia.
Methods/Findings: Thus, the current study is to investigate new molecular events (Barrett’s esophageal tissue-specific-
mtDNA alterations/instabilities) in mitochondrial genome and causative factors for their alterations using the corresponding
adjacent normal mucosal tissue (NT) and tissue (BT) from 34 patients having Barrett’s metaplasia without the presence of
dysplasia. Eighteen patients (53%) exhibited mtDNA mutations which were not found in adjacent NT. mtDNA copy number
was about 3 times higher in BT than in adjacent NT. The activity of the mitochondrial respiratory chain enzyme complexes in
tissues from Barrett’s metaplasia without the presence of dysplasia was impaired. Reactive oxygen species (ROS) level in BT
was significantly higher than those in corresponding samples.
Conclusion/Significance: High ROS level in BT may contribute to the development of mtDNA mutations, which may play a
crucial role in disease progression and tumorigenesis in BE.
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Introduction
Patients with Barrett’s esophagus (BE) have a 30 to 125-fold
higher risk of developing esophageal adenocarcinoma (EA) than
those without this lesion. The presence of BE confers a 0.5,1%
per year risk of the development of EA [1–5]. The prevalence of
esophageal cancer is increasing in the world and has a poor
prognosis mainly because of presentation at late stage. Progression
to esophageal cells to cancer follows the metaplasia-dysplasia-
adenocarcinoma sequence. Barrett’s metaplasia of esophagus is
defined as replacement of the normal squamous epithelium of
distal esophagus by metaplastic glandular epithelium containing
intestinal-type goblet cells. The numerous molecular events may
play a role in the neoplastic transformation of Barrett’s mucosa
such as the change of DNA ploidy, p53 mutation and alteration of
adhesion molecules. However, the molecular mechanism of the
progression of BE to EA remains unclear.
The mitochondrion is an important micro-organelle that
produces the energy for cell development, differentiation and
growth by inducing apoptosis [6]. mtDNA repair system is
inefficient and there is a higher exposure to reactive oxygen
species (ROS) produced in the process of adenosine triphos-
phate (ATP) synthesis. ROS are commonly released in chronic
inflammatory tissue. mtDNA is one of the target of ROS and
free radicals [7]. With inflammation and excess stress ROS can
overwhelm the antioxidant system, which result in damage to
mtDNA [6,8]. Accumulation in mutations in mtDNA, leading
to an impairment of mitochondrial function, has been impli-
cated in the etiology of aging, several degenerative pathologies,
and tumorigenesis based on the presence of novel hetero-and
homoplasmies [9]. Somatic mtDNA mutations play a role in
oncogenic transformation and they also can contribute to tumor
progression by enhancing the metastatic potential of tumor cells
[10]. Thus, the current study is to investigate new molecular
events (Barrett’s metaplasia tissue-specific-mtDNA alterations/
instabilities) in mitochondrial genome and causative factors for
their alterations using the corresponding adjacent normal
mucosal tissues and metaplasia tissue from Barrett’s metaplasia
without the presence of dysplasia.
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mtDNA Sequence Alterations
In a set of analyses of the mtDNA control region obtained from
adjacent NT and BT, characteristic heteroplasmic substitution
mutations in the mtDNA control region were observed in two
patients (6%), respectively (Table 1, Fig. 1). mtDNA length
heteroplasmic mutation at poly C stretch of 303 poly C, 16189
poly C and 514 (CA) repeat were observed in 18 patients (53%)
(Table 1, Fig. 2). Overall, BT-specific mtDNA mutations were
observed in 53% (18/34) of all patients.
Spectrum of Length Heteroplasmic Mutations
A gene scan (capillary electrophoresis) showed length hetero-
plasmies in 303 poly C, 16189 poly C and 514 CA repeats which
were confirmed by TA cloning. The pattern of BT-specific length
heteroplasmic mutation at 303 poly C region was distributed into
8CT6C+9CT6C+10CT6C+11CT6C, 7CT6C +8CT6C +9CT6C
+10CT6C+11CT6C+12CT6C, 7CT6C+8CT6C,
8CT6C+9CT6C+10CT6C+11CT6C+12CT6C+13CT6C+14C-
T6C, 6CT6C+7CT6C+8CT6C+9CT6C+10CT6C, 15C +16C
+17C +18C, 14C +15C +16C +17C +18C,
8CT6C+9CT6C+10CT6C (2.9%/each) (Table 1, Fig. 2). The
pattern of BT-specific length heteroplasmic mutation at 514 (CA)
repeats in HV2 regions disclosed 4(CA) repeats (2.9%) (Table 1).
BT-specific length heteroplasmic mutation at 16189 poly C
displayed four types of patterns: 9C +10C +11C +12C,
3CT4C+5CT4C, 10C +11C +12C, 9C +10C +11C (2.9%/each)
(Table 1). Specimens that showed dissimilarities in length
heteroplasmy between patient adjacent NT and BT were 23%
(8 cases) for 303 poly C, 2.9% (1 case) for 514 (CA) repeats and
11% (4 cases) for 16189 poly C. Three patients had BT-specific
length heteroplasmic mutations arising in both 303 poly C and
16189 poly C stretch regions. One patient had BT-specific length
heteroplasmic mutations from both 303 poly C and 514 (CA)
repeats (Table 1).
Table 1. mtDNA substitution and length heteroplasmic mutations in Barrett’s metaplasia tissue (BT) and adjacent normal mucosal
tissue (NT).
Mutation
status
mtDNA
genes
or
regions Samples from patients with Barrett’s esophagus
Patient
ID No. %
NT BT %% %
Substitution Control/HV2 C174G/T 21
Control/HV2,HV1 A200G, T16136C, T16172C, A16183C 27 1
Subtotal 25 . 9
Length hetero-
plasmic
mutation
303 Poly C 8CT6C+9CT6C+10CT6C 8CT6C+9CT6C+10CT6C+11CT6C 1 1
8CT6C+9CT6C+10CT6C 7CT6C+8CT6C+9CT6C+10CT6C+11CT6C+12CT6C 2 1
7CT6C+8CT6C+9CT6C 7CT6C+8CT6C 5 1
8CT6C+9CT6C+10CT6C+11CT6C
+12CT6C
8CT6C+9CT6C+10CT6C+11CT6C+12CT6C+13CT6C
+14CT6C
91
6CT6C+7CT6C+8CT6C 6CT6C+7CT6C+8CT6C+9CT6C+10CT6C 12 1
15C+16C+17C+18C+19C+20C 15C+16C+17C+18C 13 1
7CT6C+8CT6C+9CT6C 14C+15C+16C+17C+18C 16 1
8CT6C+9CT6C 8CT6C+9CT6C+10CT6C 34 1
16189 Poly C 9C+10C+11C+12C+13C 9C+10C+11C+12C 15 1
4CT4C+5CT4C 3CT4C+5CT4C 17 1
9C+10C+11C+12C 10C+11C+12C 21 1
10C+11C 9C+10C+11C 31 1
514 CA CA4+CA5 CA4 32 1
303 Poly C 7CT6C+8CT6C+9CT6C+10CT6C 5CT6C+6CT6C+7CT6C+8CT6C+9CT6C 8 1
16189 Poly C 9C+10C+11C+12C+13C 10C+11C+12C+13C
303 Poly C 8CT6C+9CT6C+10CT6C+11CT6C 7CT6C+8CT6C+9CT6C+10CT6C 26 1
16189 Poly C 5CT4C 4CT4C+5CT4C
303 Poly C 8CT6C+9CT6C+10CT6C+11CT6C+12CT6C 13C+14C+15C+16C+17C 27 1
16189 Poly C 9C+10C+11C+12C+13C 10C+11C+12C+13C
303 Poly C 6CT6C+7CT6C+8CT6C+9CT6C+10CT6C 8CT6C+9CT6C+10CT6C 33 1
514CA CA4+CA5 CA4
Subtotal 18 52.9
Total 18 52.9
doi:10.1371/journal.pone.0037571.t001
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The mtDNA copy number (molecules/ul) from BT and
adjacent NT showed 4.75612.14, 1.2260.78 (Fig. 3). The
mtDNA copy number was significantly increased in BT than
adjacent NT (P=0.01).
Hydrogen Peroxide Content
Hydrogen peroxide was measured from BT and corresponding
adjacent NT specimen to investigate the cause of BT-specific
mtDNA mutations founded in the current study. The level of
hydrogen peroxide significantly elevated in supernatants from BT
(90.1650.7 lM/mg protein) compared with those from adjacent
NT (48.9617.6 lM/mg protein) (Fig. 4). The level of hydrogen
peroxide in the BT was significantly higher than those from the
corresponding samples (P=0.017).
Quantitation of mtDNA Large (4977 bp) Deletion
mtDNA large (4977 bp) deletion in BT and matched adjacent
NT were quantified using gene scan and real-time PCR which
were developed in the current study. The amounts of mtDNA
large deletion were significantly increased in BT compared with
those from adjacent NT (P=0.04) (Fig. 5).
Functional Alteration of Respiratory Chain Enzyme
Complex Activity in Barrett’s Tissue
The activity of mitochondrial respiratory chain enzyme
complexes in Barrett’s tissue was impaired in comparison with
those of the adjacent normal mucosa: Decreased enzyme activity
Figure 1. mtDNA substitution mutations only found in Barrett’s
metaplasia tissue. Sequencing chromatograms showed Barrett’s
metaplasia tissue (BT)-specific mtDNA mutations which were only
observed in BT. Heteroplasmic mtDNA mutations were observed in HV2
from patient’s No. 2 and 27. These heteroplasmic mutations were not
found in the corresponding adjacent normal mucosal tissue (NT).
doi:10.1371/journal.pone.0037571.g001
Figure 2. mtDNA length heteroplasmic mutations in Barrett’s metaplasia tissue. A gene scan analysis of the poly C stretch region at
nucleotide position (np) 303 - 315 (A), np 16184 - 16193 (B) and (CA) repeat starting at np 514 (C) from Barrett’s metaplasia tissues (BT) compared to
those from adjacent normal mucosal tissue (NT) demonstrated typical length heteroplasmic mutations in the poly C stretch regions from patient’s
No. 33, 15 and 32 respectively.
doi:10.1371/journal.pone.0037571.g002
mtDNA Mutations in Barrett’s Metaplasia
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Barrett’s tissue (Table S3).
Discussion
Carcinogenesis is a long-term, multistep process driven by
genetic and epigenetic changes in susceptible cells, which gain a
selective growth advantage and undergo clonal expression [11].
BE is a premalignant condition that predisposes to the develop-
ment of EA. It is detected on endoscopy and confirmed
histologically by the presence in the lower esophagus of a
metaplastic mucosa, the so-called specialized epithelium, which
resembles incomplete intestinal metaplasia in the stomach. The
similarities with incomplete intestinal metaplasia is present on
histology, mucin histochemistry and immunohistochemistry with
various differentiation markers (cytokeratins and MUC antigens).
On morphology, the carcinogenetic process of Barrett’s mucosa
progresses through increasing grades of epithelial dysplasia.
Dysplasia, a synonym of intraepithelial neoplasia, is the only
marker that can be used at the present time to delineate a
population of patients at high risk of cancer.
Although high-grade dysplasia is considered a precursor to
invasive adenocarcinoma, detection of this abnormal mucosa
remains controversial and currently requires esophagoscopy with
biopsy. It has been suggested that epithelial markers, such as
increased activity of mucosal ornithine decarboxylase, sulfomucin
production, nuclear DNA aneuploidy, and recently molecular
analysis, have also been proposed to identify patients at increased
risk for malignant degeneration [12].
Similar to other malignant tumors, carcinogenesis of EA is
characterized by several genetic and epigenetic alterations with
genetic instability (e.g., loss of heterozygote and/or ploidy),
abnormal expression profiles of oncogenes (e.g., c-myc, VEGF
and its receptors) and alterations in the DNA-methylation pattern
(e.g., hypermethylation of p16, TIMP-3, DAPK, SOCS1 and
SOCS3, and hypomethylation of CDX1. Molecular changes are
early events in Barrett’s pathogenesis. The prevalence of these
molecular alterations increases during the malignant transforma-
tion from BE to dysplasia and EA. Although for the majority of
hitherto identified genes, the predictive or prognostic value
remains unclear. Nearly all of the new markers are not yet
validated in prospective controlled or randomized studies [13].
Among the numerous molecular events that have been shown to
playaroleintheneoplastictransformationofBarrett’smucosa,only
changesinDNAploidy,increasedproliferation,andalterationsofthe
p53 gene have been suggested to be of potential help in the
carcinogenesis[14].Asmentionedinintroduction,mtDNAmutation
has beenregarded as oncogenic factors[15]. However, the study on
mitochondrialdysfunctionandmtDNAmutationwaspaucityinBE.
Themitochondrionisanimportantmicrorganellethatproducesthe
Figure 3. Significant increase in mtDNA copy number in
Barrett’s metaplasia tissue. Quantitation of mtDNA copy number
was calculated from the ratio of copy number (copies/ml) from mtDNA
cytochrome b and nuclear ß-actin gene using real-time PCR. The
average mtDNA copy number was significantly increased in Barrett’s
metaplasia tissues (BT) compared to those from adjacent normal
mucosal tissues (NT) (P=0.01).
doi:10.1371/journal.pone.0037571.g003
Figure 4. Production of high level of reactive oxygen species in
Barrett’s metaplasia tissue. Quantitative determination of reactive
oxygen species (hydrogen peroxide) from supernatants of Barrett’s
metaplasia tissue (BT) and adjacent normal mucosal tissue (NT) was
measured by commercial kit (Bioxytech H2O2-560). The level of
hydrogen peroxide was significantly elevated in supernatants from BT
compared with those from adjacent NT (P=0.017).
doi:10.1371/journal.pone.0037571.g004
Figure 5. Increase of mtDNA large (4977 bp) deletions in
Barrett’s metaplasia tissue. The amounts of mtDNA large deletions
were significantly increased in Barrett’s metaplasia tissue (BT) compared
with those from matched adjacent normal tissue (NT).
doi:10.1371/journal.pone.0037571.g005
mtDNA Mutations in Barrett’s Metaplasia
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inducingapoptosis.HumanmtDNAcontains16,569basepairsand
represents 0.1,1.0% of the total genomic DNA. A mammalian cell
contains approximately 1,000 mitochondria, and each mitochon-
drion contains 2 to 10 DNA copies. There is a 10,20 fold greater
susceptibility of mtDNA to genetic mutation because mtDNA does
not contain introns in comparison to nuclear DNA, the mtDNA
repair system is inefficient and there is a higher exposure to ROS
produced in the process of ATP synthesis. ROS plays an important
role as potential carcinogens in the pathogenesis of GERD, BE and
gastritis [16]. Oxidative damage has long been related to mucosal
damagesofgastrointestinaltractsandtheirensuingcarcinogenesis.In
spite of treatment with anti-secretory medications for reflux
esophagitis, considerable portions of patient did not achieve the
complete mucosal healings orsuffered from sustaining symptoms or
development of dread complication like BE, suggesting other
damaging factors or impaired mucosal resistance are also involved
intheir pathogenesis[17,18].
BE occurs due to chronic inflammation which is mainly caused
by GERD. An increase in ROS production frequently happens in
chronic inflammatory cells and tissue. Thus, the current study
attempted to detect BT-specific mtDNA alterations with the
assumption that mtDNA aberrations are caused by ROS
abundantly produced in chronically inflamed BT. mtDNA
mutations in the current study were detected exclusively in BT
samples but not in adjacent NT. These mtDNA mutations were
observed as base substitutions and length heteroplasmy in the
control region containing. The oxidative stress elicited by chronic
inflammation increases the number of mtDNA mutations in BT
and might correlate with a precancerous status [19]. The level of
ROS was significantly higher in the supernatants obtained from
BT compared with those from the adjacent NT. This high level of
ROS might damage the mitochondria, leading to mtDNA
mutations. mtDNA control region contains the mtDNA produc-
tion regulating fraction and HV region known as a ‘hot spot’ of
gene mutation in various degenerative diseases and tumors [20].
Recent reports have showed that severe morphological and
functional alterations of cells and tissue are accompanied by a
decrease of mtDNA copy number [6]. This is known to be a
consequence of mtDNA mutation in the region near the
replication origin of mtDNA. In contrast, it has been reported
that the number of mtDNA copies increases if ATP synthesis is
hindered by aging or chronic inflammation [6]. Concurrent with
these reports, the number of mtDNA copies measured in BT was
approximately four times higher than those in corresponding
adjacent NT in the current study.
Recently one study reports that the frequency of specimens with
the 4977 bp deletion increased in relation to the degree of
dysplasia, so the mtDNA 4977 bp deletion may be useful as a
biomarker to detect the severity [9]. The current study also
confirms that the amounts of mtDNA large deletion were
significantly increased in BT compared with those from either
matched adjacent NT.
Importantly, mutations in the control region might alter the rate
of DNA replication by modifying the binding affinity of significant
trans-activating factors. These mtDNA alterations in BT might
further impair a respiratory chain defect resulting in increasing the
mtDNA copy number to compensate for the deficiency in ATP.
During this perturbation, mitochondria might produce a large
amount of ROS, which causes the vicious cycle observed in other
chronic inflammatory diseases [17].
BT-specific mtDNA mutations frequently occurred in both the
mtDNA control and minisatellite regions due to excessive
production of ROS. High level of ROS in BT may contribute
to development of mtDNA mutations, which may play a crucial
role in pathophysiology of BE and furthermore progression to EA.
Although many risk factors are considered in BE and EA,
antioxidant treatment seems to be the therapeutics in the
prevention or treatment of BE and moreover it plays the
preventive role in disease progression.
Materials and Methods
Patient Specimens and Tissue Staining
Thirty-four patients were enrolled after receiving Institutional
Review Board approval and informed consent. Matched Barrett’s
metaplasia tissue (BT) and adjacent normal mucosal tissue (NT)
was obtained during the endoscopic procedure (Table S1). A
diagnosis of BE was based on findings of endoscopy and
specialized intestinal metaplasia on Hematoxylin and Eosin
(H&E) stained tissue. Following standard tissue preparation, tissue
was embedded in paraffin and was sliced with a microslicer. Sliced
tissue was embedded into slides and stained with H&E (Fig. 6).
Direct Sequencing of mtDNA Control Region
BT was obtained in a test tube containing 5 ml phosphate
buffered saline (PBS, pH 7.4), sliced into small pieces with a
sterilized mesh, and dissolved in protease K and tissue lysis buffer
solution, from which DNA was extracted. Extracted total DNA
was then dissolved in TE buffer (10 mM Tris-HCl, 1 mM
Na2EDTA, pH 8.0) and was quantified with the use of a
spectrophotometer. Published protocol was used to amplify and
sequence mtDNA control region [20]. The mtDNA sequences
obtained were analyzed using the Revised Cambridge Reference
Sequence (http://www.mitomap.org/), Blast2 program (http://
www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi) and MitoAnaly-
zer (http://www.cstl.nist.gov/biotech/strbase/mitoanalyzer.html)
to determine mtDNA aberrations (Table S2).
Determination of mtDNA Length Heteroplasmies in the
Control Region
mtDNA minisatellites are located in the mtDNA non-coding
hypervariable regions (HV) 1 and 2. Size-based amplified product
separation by capillary electrophoresis based on published
protocol was performed in order to detect length heteroplasmic
mutations of 16189 poly C (
16184CCCCCTCCCC
16193, 5CT4C),
303 poly C (
303CCCCCCCTCCCCC
315, 7CT5C) and 514 (CA)
repeat (
514CACACACACA
523, (CA)5 repeats) [20,21] (Table S2).
TA Cloning for Confirmation of Length Heteroplasmic
Mutations
The procedure including a set of primer pairs and PCR
conditions was carried out according to the published protocol
[22]. Each purified PCR product of 303 poly C, 16189 poly C and
514 (CA) repeat was inserted into pGEM-T Easy Vector
(Promega, Madison, WI, USA). Competent E. coli (JM 109 cells)
were then transformed with the plasmids containing the PCR
product inserts. White colonies (8 to 12) including recombinant
plasmids were selected and cultured. After plasmids extraction,
length heteroplasmic mutations were determined by DNA
sequencing (Table S2).
Quantification PCR for Determination of mtDNA Copy
Number
To generate a standard curve for quantification of mtDNA,
purified PCR product of CYTB and b-actin gene as internal
standard were inserted into pGEM-T easy vector and E. coli JM
mtDNA Mutations in Barrett’s Metaplasia
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recombinant plasmids. A mixture of 25 ml containing 12.5 mlo f
26Quantitect SYBR green PCR master mix (Qiagen, Valencia,
CA, USA), 400 mM CYTB primers F14909 (59-TACTCACCA-
GACGCCTCAACCG-39) and R15396 (59-TTATCGGA
ATGGGAGGT GATTC-39) and 6 ng of total DNA was used
for PCR with the Rotor-Gene real-time centrifugal DNA
amplification system (Corbett Research, Sydney, Australia). For
PCR, hot start reactions at 50uC for 2 min and at 95uC for 15 min
were followed by 35 cycles of 20 sec at 94uC, 30 s at 56uC, 30 s at
72uC and a melting reaction with a decrease of 1uC per cycle
between 72uC and 92uC. The mtDNA copy number was
calculated using the following formula: {X mg/ml plasmid DNA/
4419 (plasmid length)6660}66.022610
23= Y molecules/ul. The
X represents the concentration of plasmid DNA and the Y
represents copy number. The mtDNA copy number was reported
as the ratio of CYTB and b-actin gene.
Quantitative Determination of Hydrogen Peroxide
BT and adjacent NT were homogenized in 500 ml of ice-cold
deionized water. An aliquot of homogenate was taken for protein
measurement. After centrifugation at 20006g for 15 min, an
aliquot of 200 ml from supernatant was transferred to new tube.
Hydrogen peroxide content (lM/mg protein) from supernatant is
measured using the commercial kit (Bioxytech_ H2O2-560TM,
OXIS International, Foster City, CA, USA) according to the
manufacturer’s instructions.
mtDNA Large(4977 bp) Deletion
For generation of a fluorescent labeled 113 bp fragment of
the undeleted mtDNA primers int1F-3448(59-HEX-
CCCTTCGCTGACGCCATA-39) and int2R-3560 (59-AGTA-
GAAGAGCGATGGTGAGAGC-39) were used. Primers del1F-
8395 (59-HEX-CACCATAATTACCCCCATACTCCTTA-39)
and del2R-13494 (59-GAGGAAAGG TATTCCTGCTAATGC-
39) were designed to flank the deletion breakpoints and were used
to amplify a fluorescent labeled 123 bp amplicon of deleted
mtDNA. For PCR, a 50 ml mixture containing 50 ng DNA,
200 mM dNTPs, 25 pmol primary primers, 2.5 U Taq DNA
polymerase (TaKaRa LA Taq) and 5 ml1 0 6 buffer. An initial
denaturation step at 96uC for 5 min was followed by 20(int) cycles
and 45(del) cycles of 15 s at 95uC, 20 sec at 60uC, 20 sec at 72uC
and a 5 min extension step at 72uC. Specific fragments for intact
and deleted mtDNA were amplified in two different PCR
reactions in a thermal cycler (GeneAmp 2400, Applied Biosystems,
Weiterstadt, Germany). After PCR was finished, a 1 ml aliquot of
each PCR product and 0.5 ml of the internal size standard GS500
(Applied Biosystems) labeled with the fluorescent dye ROX
(Applied Biosystems) were added to deionized formamide.
Denaturation was performed at 96uC for 10 min followed by a
cooling step at 222uC for 2 min. Denatured PCR products were
separated by capillary electrophoresis using the ABI Prism
3130XL genetic analyzer (Applied Biosystems). When the run
was completed, specific fragments were displayed as peaks in an
electropherogram using the Gene Scan Analysis Software 3.1.
Quantitative PCR was conducted with a Rotor-Gene real-time
centrifugal DNA amplification system (Corbett Research), at a
final reaction volume of 25 ml containing 12.5 mlo f2 6QuantiTect
SYBR Green PCR master mix (Qiagen), DW, 10 pmol each of
the forward primer del-lF (59-CACCATAATTACCCCCA-
TACTCCTTA-39) and reverse primers del-2R (59 GAG-
GAAAGGTATTCCTGCTAATGC-39) and other mixture int-
1F (59-CCCTTCGCTGACGCCATA-39), int-2R (59-AGTA-
GAAGAGCGATGGTGAGAGC-39) for 2 ml of template DNA.
After denaturation at 95uC for 15 min, the reaction mixture was
cycled 45 cycles at 95uC for 15 sec, 58uC for 30 sec and 72uC for
90 sec. PCR was performed for 45 cycles (deletion primer-1F/2R)
and 20 cycles (intact primer-1F/2R). The percentage of the
4977 bp deletion was calculated according to the following
formula: f (dmtDNA) = Admt/Amt61.9608
CDmt/
1.9613
CDdmt6123/113. The followings are abbreviations and
explanations for aforementioned formula: f (dmtDNA), frequency
of the 4977 bp deletion; Admt, value of peak area of deletion-
specific peak; Amt, value of peak area of specific peak of intact
mtDNA; CDdmt, number of cycles necessary to detect the
4977 bp deletion; CDmt, number of cycles necessary to detect
intact mtDNA.
Determination of Activity of Mitochondrial Respiratory
Chain Enzyme Complexes
Cell homogenates were diluted to 1 g/L total protein with
20 mmol/L potassium phosphate buffer (pH 7.2) before respira-
Figure 6. Endoscopic finding and histological examination of Barrett’s metaplasia. Endoscopic finding of esophagus shows irregular Z-
line, elongated salmon patched tongue like projection of distal columnar epithelium (A). Histological examination (x200) of esophageal lesion reveals
surface glandular epithelium with tall columnar cells punctuated by round to oval goblet cells (I). The columnar epithelium resembles intestinal
epithelium but is not identical in nature. Barrett’s metaplasia is also characterized by universal presence of chronic inflammation (II) (B).
doi:10.1371/journal.pone.0037571.g006
mtDNA Mutations in Barrett’s Metaplasia
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previously published spectrophotometric methods [23].
Statistical Analysis
Descriptive data were expressed as mean 6 standard deviation.
The non-parametric Kruskal-Wallis test was used for the
determination of statistical difference in the mtDNA copy number
and hydrogen peroxide content between three specimens (BT and
adjacent NT). P-value that is lower than 0.05 was considered as
statistically significant.
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